Cited by

• Fluvastatin and hepatic reactions: a signal from spontaneous reporting in Italy.

  Conforti A, Magro L, Moretti U, Scotto S, Motola D, Salvo F, Ros B, Leone R. Conforti A, et al. Drug Saf. 2006;29(12):1163-72. doi: 10.2165/00002018-200629120-00007. Drug Saf. 2006. PMID: 17147462
• Data mining in pharmacovigilance: lessons from phantom ships.

  Hauben M, Reich L, Van Puijenbroek EP, Gerrits CM, Patadia VK. Hauben M, et al. Eur J Clin Pharmacol. 2006 Nov;62(11):967-70. doi: 10.1007/s00228-006-0181-4. Epub 2006 Aug 3. Eur J Clin Pharmacol. 2006. PMID: 16896782 No abstract available.
• Rapid identification of myocardial infarction risk associated with diabetes medications using electronic medical records.

  Brownstein JS, Murphy SN, Goldfine AB, Grant RW, Sordo M, Gainer V, Colecchi JA, Dubey A, Nathan DM, Glaser JP, Kohane IS. Brownstein JS, et al. Diabetes Care. 2010 Mar;33(3):526-31. doi: 10.2337/dc09-1506. Epub 2009 Dec 15. Diabetes Care. 2010. PMID: 20009093 Free PMC article.
• Sources of Safety Data and Statistical Strategies for Design and Analysis: Postmarket Surveillance.

  Izem R, Sanchez-Kam M, Ma H, Zink R, Zhao Y. Izem R, et al. Ther Innov Regul Sci. 2018 Mar;52(2):159-169. doi: 10.1177/2168479017741112. Epub 2018 Jan 8. Ther Innov Regul Sci. 2018. PMID: 29714520 Free PMC article. Review.
• Gathering and exploring scientific knowledge in pharmacovigilance.

  Lopes P, Nunes T, Campos D, Furlong LI, Bauer-Mehren A, Sanz F, Carrascosa MC, Mestres J, Kors J, Singh B, van Mulligen E, Van der Lei J, Diallo G, Avillach P, Ahlberg E, Boyer S, Diaz C, Oliveira JL. Lopes P, et al. PLoS One. 2013 Dec 11;8(12):e83016. doi: 10.1371/journal.pone.0083016. eCollection 2013. PLoS One. 2013. PMID: 24349421 Free PMC article.